DCGI

The Drug Controller General of India (DCGI) has directed regulators to take steps to curb black marketing of remdesivir following a complaint black marketing and overpricing of antiviral drug by certain unscrupulous persons.

Sun Pharmaceutical Industries Ltd and includes its subsidiaries and/or associate companies) has announced that it has received approval from the Drugs Controller General of India (DCGI) to initiate a clinical trial with Nafamostat Mesilate in Covid-19 patients. Nafamostat is approved in Japan for improvement of acute symptoms of pancreatitis and treatment of Disseminated Intravascular Coagulation (DIC).

Government of India has taken a series of steps as part of its 'Digital India' initiative. In pursuance of this, the Ministry of Health and Family Welfare has also been making efforts to leverage Information and Communication Technology for improving efficiency and effectiveness of the healthcare delivery in the country.